Pharmaceuticals News and Research

RSS

NanoSmart receives USPTO Notice of Allowance for cancer tumor targeting technology

NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.

16 Aug 2010

Medco Health Solutions to acquire United BioSource Corporation

Medco Health Solutions, Inc. and United BioSource Corporation today announced a definitive agreement under which Medco will acquire closely held UBC in an all-cash transaction valued at approximately $730 million. The combination of America's leading advanced pharmacy with one of the world's most respected sources of post-approval drug and device research extends Medco's core capabilities in data analytics and research to further accelerate pharmaceutical knowledge – advancing patient safety and furthering evidence-based medicine.

16 Aug 2010

Lotus Pharmaceuticals second-quarter net income increases 32% to $6.3 million

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, reported today its financial results for the quarter and six months ended June 30, 2010.

16 Aug 2010

Jiangbo receives Shandong FDA approval to market Felodipine SR tablets

Jiangbo Pharmaceuticals, Inc., today announced that the Company received approval from the Shandong Food and Drug Administration to start the sales of Felodipine sustained release tablets.

16 Aug 2010

Weikang Bio-Technology second-quarter revenue decreases 20.5% to $10.5 million

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced its fiscal 2010 second quarter results for period ended June 30, 2010.

16 Aug 2010

Cortex second-quarter net loss decreases to $0.04 per share

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $2,454,000, or $0.04 per share, for the quarter ended June 30, 2010, compared with a net loss applicable to common stock of approximately $2,778,000, or $0.06 per share, for the corresponding prior year period.

16 Aug 2010

Titan Pharmaceuticals second-quarter net loss increases to $1.84 million

Titan Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010.

16 Aug 2010

NeoStem second-quarter revenues increase 26% to $19.4 million

NeoStem, Inc. an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units, U.S. adult stem cells, China adult stem cells, and China pharmaceuticals is today providing results of its second quarter 2010.

16 Aug 2010

AMRI selected as inaugural winner of Pfizer Route Design Innovation Award

AMRI announced today that it has been selected as the inaugural winner of the Pfizer Route Design Innovation Award, beating out 40 companies who were invited to share innovative ideas for process chemistry and large scale Active Pharmaceutical Ingredient production. Pfizer will present the company with the award at the AMRI 2010 Integrated Drug Discovery Symposium to be held in Albany NY, October 13-14. AMRI will also receive an honorarium for its win.

16 Aug 2010

EntreMed second quarter 2010 net loss increases to $0.62 per share

EntreMed, Inc.,a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2010.

16 Aug 2010

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health. The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

16 Aug 2010

China Jo-Jo Drugstores reports highest first quarter revenues, gross profit and operating income to date

China Jo-Jo Drugstores, Inc.("Jo-Jo Drugstores" or the "Company"), which operates a retail pharmacy chain in the People's Republic of China (the "PRC"), today reported its financial results for the fiscal quarter ended June 30, 2010.

16 Aug 2010

A.P. Pharma second quarter 2010 net loss decreases to $0.09 per share

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2010.“We are working expeditiously to complete the work needed to prepare for a meeting with the FDA. Once the necessary information is available, we will request an End of Review meeting to discuss the next steps for the APF530 New Drug Application.”

16 Aug 2010

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222. This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

16 Aug 2010

China Biologic Products second-quarter revenues increase 23.3% to $40.9 million

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., today reported financial results for its second quarter ended June 30, 2010.

16 Aug 2010

Green Cross receives KFDA approval to manufacture, market i.v. peramivir: BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. announced that its partner, Green Cross Corporation has received marketing and manufacturing approval from KFDA for intravenous peramivir to treat patients with influenza A & B viruses, including pandemic H1N1 and avian influenza. Green Cross Corp. intends to launch peramivir under the commercial name PeramiFlu in South Korea.

16 Aug 2010

ISCT partners with leading companies in cell therapy regenerative medicine market to drive clinical development

Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.

16 Aug 2010